SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Weibull Caroline E)
 

Sökning: WFRF:(Weibull Caroline E) > Comorbidities and s...

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study

Glimelius, Ingrid, 1975- (författare)
Karolinska Institutet,Uppsala universitet,Karolinska Institute,Department of Medicine, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital,Uppsala University Hospital,Experimentell och klinisk onkologi
Smedby, Karin E. (författare)
Karolinska Institutet,Karolinska Institute,Karolinska University Hospital
Eloranta, Sandra (författare)
Karolinska Institute,Karolinska University Hospital
visa fler...
Jerkeman, Mats (författare)
Lund University,Lunds universitet,Skåne University Hospital
Weibull, Caroline E. (författare)
Karolinska Institutet,Karolinska Institute,Karolinska University Hospital
visa färre...
 (creator_code:org_t)
2019-11-13
2019
Engelska.
Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141.
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The prognosis for mantle cell lymphoma (MCL) remains poor. Our aim was to assess the impact of comorbidities on survival and causes of death. For 1,385 MCL patients (1,009 males, 376 females) diagnosed in 2000–2014 (median age 71 years, range 22–96) comorbidities ≤ 10 years of diagnosis were classified according to the Charlson comorbidity index (CCI; 0, 1, 2+). Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to compare lymphoma-specific and all-cause mortality rates. Model-based predictions were used to obtain probabilities of death. Overall, 44% had any comorbidity (CCI 1+) and 28% severe comorbidity (CCI 2+). Over a median follow-up of 3·7 years (range 0–16), 633 (46%) died, the majority (76%) from lymphoma. Severe comorbidity was independently associated with higher all-cause [hazard ratio (HR) = 1·52; 95% CI: 1·24–1·85) and lymphoma-specific mortality (HR = 1·31; 95% CI: 1·04–1·65). Particularly among patients with connective tissue, renal and psychiatric diseases, and dementia. Among females with any comorbidity, non-lymphoma deaths represented a larger proportion of all deaths, compared to males with any comorbidity. In general, more efficient lymphoma treatments need to be considered also for patients with severe comorbidity. However, among females with any comorbidity, the likelihood of non-lymphoma death was still considerable, perhaps favouring a more liberal use of a “wait and watch” approach.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

cause of death
comorbidity
lymphoma-specific mortality
mantle cell lymphoma
sex
cause of death

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy